



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1693-O)

In the Application of: )  
Beck et al. )  
Serial No. 09/896,139 ) Examiner: Richard L. Raymond  
Filed: June 29, 2001 ) Art Unit: 1624  
For: Compounds to Treat )  
Alzheimer's Disease )

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

### U.S. Documents

1. U.S. Patent No. 5,703,129, issued December 30, 1997.
2. U.S. Patent No. 5,886,046, issued March 23, 1999.

### Foreign Documents

3. WO 98/38167, published September 3, 1998.
4. WO 96/35414, published November 14, 1996.

### Other Documents

5. D.L. Flynn et al., J. Am. Chem. Soc., Vol. 119, No. 21, 1997, pgs. 4874-4881
6. Haga et al., Chemical and Pharmaceutical Bulletin, Vol. 40, No. 12, 1992, pgs. 3349-3351
7. Raddatz et al., J. of Med. Chem., Vol. 34, No. 11, 1991, pgs. 3267-3280
8. Nishi et al., Chemistry Letters, 1989, pgs. 1993-1996
9. Harbeson et al., J. of Med. Chem., Vol. 32, No. 6, 1989, pgs. 1378-1392
10. Thaisrivongs et al., J. Med. Chem., Vol. 31, No. 7, 1988, pgs. 1369-1376
11. Nakano et al., Bulletin of the Chemical Society of Japan, Vol. 63, No. 8, 1990, pgs. 2224-2232
12. Kaltenbronn et al., J. Med. Chem., Vol. 33, No. 2, 1990, pgs. 838-845
13. Chen et al., J. Med. Chem., Vol. 39, No. 10, 1996, pgs. 1991-2007
14. Plummer et al., Bioorganic & Medicinal Chemistry Letters, Vol. 9, 1999, pgs. 835-840

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-

1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

Dated: June 7, 2005

By: Bradley W. Crawford  
Bradley W. Crawford  
Reg. No. 50,494


McDonnell Boehnen Hulbert & Berghoff LLP  
300 S. Wacker Drive, Suite 3200  
Chicago, IL 60606  
Telephone: (312) 913-0001  
Facsimile: (312) 913-0002

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Atty. Docket No.

01-1693-0

Serial No.

09/896,139

**Applicant:**

Beck, et al.

**Filing Date:**

June 29, 2001

**Group:**

1624

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	5,703,129	12/30/1997	Felsenstein et al.			
	2.	5,886,046	3/23/1999	Hirschmann et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation
							Yes      No
	3.	WO 98/38167	9/3/1998	PCT			
	4.	WO 96/35414	11/14/1996	PCT			


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)



U.S. Department of Commerce  
Patent and Trademark Office

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

01-1693-0

Serial No.

09/896,139

**Applicant:**

Beck, et al.

**Filing Date:**

June 29, 2001

**Group:**

1624

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).**

5.	D.L. Flynn et al., J. Am. Chem. Soc., Vol. 119, No. 21, 1997, pgs. 4874-4881
6.	Haga et al., Chemical and Pharmaceutical Bulletin, Vol. 40, No. 12, 1992, pgs. 3349-3351
7.	Raddatz et al., J. of Med. Chem., Vol. 34, No. 11, 1991, pgs. 3267-3280
8.	Nishi et al., Chemistry Letters, 1989, pgs. 1993-1996
9.	Harbeson et al., J. of Med. Chem., Vol. 32, No. 6, 1989, pgs. 1378-1392
10.	Thaisrivongs et al., J. Med. Chem., Vol. 31, No. 7, 1988, pgs. 1369-1376
11.	Nakano et al., Bulletin of the Chemical Society of Japan, Vol. 63, No. 8, 1990, pgs. 2224-2232
12.	Kaltenbronn et al., J. Med. Chem., Vol. 33, No. 2, 1990, pgs. 838-845
13.	Chen et al., J. Med. Chem., Vol. 39, No. 10, 1996, pgs. 1991-2007
14.	Plummer et al., Bioorganic & Medicinal Chemistry Letters, Vol. 9, 1999, pgs. 835-840

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.